Document:

PRODUCTION AGREEMENT, DATED JANUARY 6, 2012

 Exhibit 10.1 
 ASKION PRODUCTION AGREEMENT 
 This Production Agreement (“this
Agreement”) dated as of January 6, 2012 (the “Effective Date”), is entered into by MELA Sciences, Inc. (f/k/a Electro-Optical Sciences, Inc.), a corporation organized and existing under the laws of the State of Delaware with its
principal business address at 50 South Buckhout Street, Suite 1, Irvington, New York 10533 (“MELA”) and Askion GmbH, a German Company with limited liability with its registered office at Gewerbepark Keplerstraße 17-19, D-07549 Gera,
Federal Republic of Germany (“Askion”), each of which is individually referred to as a “Party” and both of which are sometimes collectively referred to as “Parties”. 

RECITALS: 
 A. MELA is a medical device company focused on the design, development and commercialization of MelaFind®, a non-invasive, point-of-care instrument to assist in the detection of early melanoma. Askion has experience and expertise in the design, engineering, and
manufacture of precision optics and related components for the health care industry. 
 B. Upon and subject
to the terms and conditions of this Agreement, MELA desires to retain Askion’s services to manufacture, integrate, and test certain components, assemblies and systems of MELA’s product known as MelaFind®. 
 ARTICLE I 
 MANUFACTURING AND TESTING OBLIGATIONS 

1.1 RESPONSIBILITIES. MELA is engaging Askion, and Askion agrees, pursuant to this Agreement to manufacture and test the MelaFind® Hand-held Imager (the “Imager”) and the field phantom fixture for the Imager (the “Phantom
Fixture”), as well as in certain cases the integrated finished product (the “Product”) consisting of the Imager, the Phantom Fixture and the Cart Assembly (the “Cart”), all in accordance with the Product Specifications as
set forth in Appendix I attached hereto (the “Product Specifications”). The Imager and Phantom Fixture (sometimes collectively hereinafter referred to as the “Matched Pair”) and the Product shall be tested by Askion in accordance
with Testing Procedures in Appendix II attached hereto (the “Testing Procedures”). The Product Specifications and the Testing Procedures may be modified pursuant to Section 1.4 below. The services to be rendered by Askion
(i) with respect to the Imager and the Phantom Fixture are manufacturing, integration, testing, warehousing, packaging/crating, shipping, service and repair and (ii) with respect to the Product are manufacturing, integration, testing,
warehousing, labeling, packaging/crating, shipping, field service & customer support, service and repair. These services are collectively referred to herein as the “Manufacturing and Testing Services.” Both during the Term (as
defined in Section 4.1) and following termination or expiration of this Agreement for any reason, Askion shall not supply the Product, or any component thereof, including the Imager and the Phantom Fixture to any third party. In addition, both
during the Term (as defined in Section 4.2) and for a period of five years following termination or expiration of this Agreement for any reason, Askion shall not supply any product similar to the

 
Product (or any prototype thereof) of the same field of application or any similar service to any third party whatsoever. In no event, either during the Term or thereafter shall Askion utilize
any intellectual property that would violate the terms of Article VI hereof, including without limitation any Inventions as defined in Article IV. All Product shall be produced with MELA’s logo imprinted or molded thereon, as the relevant
Product Specifications may require. Askion shall deliver to MELA a monthly status report with respect to its performance of the Manufacturing and Testing Services by electronic mail with such detail as set forth on Appendix III attached hereto or as
MELA requests. Such Manufacturing and Testing Services shall comport with the timing and scheduling set forth on applicable MELA approved purchase orders. Askion will also provide inventory management of finished goods, MELA owned components and
accessories at its facility as part of the warehousing services for MELA. 
 1.2 MANUFACTURING. This Agreement has been entered into on the
basis that, subject to the terms of this Agreement, Askion will manufacture and sell to MELA the Matched Pairs and/or Products as required, and requested by MELA in such quantities of the Matched Pairs and/or Products as ordered by MELA pursuant to
approved purchase orders. Askion will perform all work necessary to procure components and manufacture the Matched Pairs and/or Products in accordance with the Product Specifications unless specifically directed otherwise by MELA in writing.

 1.3 COOPERATION. The Parties will cooperate and keep each other informed in a timely manner, including providing appropriate documentation,
with respect to all activities directly related to this Agreement, including, without limitation, access to drawings, specifications, engineering change orders, software, supplier information, processes and material directly related to this
Agreement. The Parties agree to respond to questions and requests for clarification and approvals promptly and to notify each other of any approval or reasons for rejection within 15 days of such approval or rejection. The Parties agree that MELA
shall be entitled to have one representative on-site at Askion’s Gera, Germany facility during regular business hours throughout the Term (as defined in Section 4.1 hereof), who will be permitted to inspect the Manufacturing and Testing
Services. 
 1.4 MODIFICATIONS TO SPECIFICATIONS AND PROCEDURES. MELA reserves the right to request in writing changes to the Product
Specifications and Testing Procedures at any time. Such changes shall be effected by Askion, and Appendices I and II hereto shall be amended accordingly, unless Askion reasonably determines in good faith that such changes are not feasible, in which
case Askion shall so notify MELA promptly following MELA’s request for such changes. Askion and MELA will work together in good faith to modify the requested changes so that they are feasible. The changes as finally agreed shall be documented
in writing and Appendices I and II shall be amended accordingly. Askion will manufacture and test the Imager and the Phantom Fixture, and manufacture, test and integrate the Product, in each case to conform to all such modified Product
Specifications and/or Testing Procedures. Askion may not change the design, processes, or procedures relative to the manufacture, testing or integration of the Product, Imager or Phantom Fixture including the materials or components thereof, in any
respect without the prior written consent of MELA’s Director of Operations. To the 

  
 2 

 
extent that any modification to the Product Specifications and/or Testing Procedures reasonably warrants an adjustment to the pricing provided in Sections 1.7(a), 1.7(b) or 1.7(c) herein or time
schedules, MELA and Askion agree to negotiate in good faith an equitable adjustment for all such changes resulting from such modification to the Product Specifications and/or Testing Procedures. 

1.5 DELIVERY AND SHIPMENT. 
 (a) MELA shall
deliver written packaging & shipping instructions for each Matched Pair and each Product. Askion shall not deliver the Product and/or the Matched Pairs later or substantially earlier than the dates indicated in the relevant purchase order
or sales order. All Matched Pairs and Products shall be packed and crated by Askion in accordance with the packaging instructions set forth on Appendix III attached hereto (the “Instructions”). The Instructions may be modified by MELA in
writing from time to time, with all deliveries to MELA to be FOB Askion’s loading dock at its Gera, Germany facility, using third party logistics (3PL) specified by MELA. All risk of loss from the FOB point shall be borne by MELA. All
freight costs and customs duties shall be borne by MELA and, if such costs are prepaid by Askion, such costs shall be listed separately in the invoices provided by Askion to MELA as set forth in Section 1.8 (b) hereof. 

(b) As the sole European authorized representative for MELA with respect to the Product, Askion will be responsible for technical (not medical)
field & customer support, including customer delivery, installation and training of the Product and its accessories. All field & customer support for the Product will be provided by Askion under the guidance and approval of the
MELA’s Director of Operations. 
 1.6 SCHEDULES AND SALES FORECASTS. During the Term, MELA and Askion will jointly develop production
plans, manufacturing & test rates and scheduled deliveries based on the latest MELA sales forecasts. MELA and Askion will review every 3 months any and all changes or potential changes to the forecast versus the production plan. These
changes can include but are not limited to, historical demand analysis, regulatory changes, new demographic product positioning, promotional plans, planned or unplanned customer demand, supply chain disruptions, component end of life and risk
aversion/mitigation. This review and evaluation will be held every quarter and will be called the “Rolling 3 Month Forecast Review”. The Parties agree that a mechanism for forecasting parts which require a long lead time will be
established and agreed by the Parties. Any changes will be documented as “Meeting Minutes” and annotated in respective MELA purchase order amendments approved by both MELA and Askion. Askion shall use its best efforts to accommodate
changes requested by MELA. 
 1.7 PRICING. 
 (a) The unit price for each Matched Pair (consisting of one Imager and one Phantom Fixture) shall initially be USD $*** and shall include the manufacturing, integration, testing, packaging/crating and
warehousing for each Matched Pair. 
  

	***	This material has been omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. 

  
 3 

 This initial unit pricing shall apply to the first *** (***) Matched Pairs purchased hereunder. Thereafter
the unit pricing for each Matched Pair shall be adjusted in accordance with subsection (d) hereof and mutually determined and agreed to by the Parties, in good faith, and be set forth in a writing which shall be affixed to this Agreement and
amend the terms of unit pricing herein. The applicable pricing shall be set forth in each MELA approved purchase order for Matched Pairs. Unit pricing will be further adjusted proportionately for any and all work-in-process assemblies (WIP),
inventory and raw component materials (on hand inventory) which are the property of MELA and shall result in an upfront “discounted” unit price, the amount of which shall be agreed to by MELA and Askion. 

(b) The fee for each Product integration shall initially be USD $*** and shall include the integration, testing, packaging/crating, labeling and
warehousing for such Product. This initial fee shall apply to any Product purchased hereunder which incorporates as components the first *** (***) Matched Pairs purchased by MELA hereunder. Thereafter the fee for each Product shall be adjusted in
accordance with subsection (d) hereof and mutually determined and agreed to by the Parties, in good faith, and be set forth in a writing which shall be affixed to this Agreement and amend the terms of pricing herein. The applicable pricing
shall be set forth in each MELA approved purchase order for the Product. 
 (c) The fee for field service & customer support, including
customer delivery and installation of the Product and its accessories and customer training related thereto shall be USD $*** for each installation or field visit. This initial fee shall apply to any Product purchased hereunder which incorporates as
components the first *** (***) Matched Pairs purchased by MELA hereunder. Thereafter the fee for field service & customer support shall be adjusted in accordance with subsection (d) hereof and mutually determined and agreed to by the
Parties, in good faith, and be set forth in a writing which shall be affixed to this Agreement and amend the terms of pricing herein. 
 (d) The
Parties acknowledge that the US dollar amounts specified in subsections (a), (b) and (c) above are based on an exchange rate of USD$1.38 per 1€. To the extent that the published exchange rate of US dollars per Euro on the date of
invoicing MELA for the relevant item or service is within a range of USD$1.20 to $1.50, then the pricing shall remain the same. To the extent that the published exchange rate is outside of such range then the Parties agree to use the average of the
published exchange rates for 10 consecutive days commencing on the date which is 5 days prior to the date the exchange rate falls outside of the range. The Parties also recognize that the pricing set forth in subparagraphs (a) through
(c) hereof will be subject to numerous variables, including the relevant experience of the Parties in performing the services and agreements hereunder, and the implementation of cost saving techniques as described herein. 

 

	***	This material has been omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. 

  
 4 

 As the parties are able to quantify and agree on reasonable future estimates for the elements on which unit
pricing is based, such estimates will serve as the basis for determining pricing for production beyond the initial pricing referenced in subsections (a) through (c) above. 
 The Parties will cooperate in good faith to reduce the costs of the unit pricing by methods such as obtaining alternate sources of materials, reducing the cost of materials from current suppliers,
revising product specifications, and improving integration, manufacturing or test methods. The Parties shall mutually agree on all cost-reduction methods prior to their implementation, it being understood that quality shall not be compromised.
In order to optimize the costs of production while maintaining optimal functionality of the Imagers, Phantom Fixtures and Products, MELA will provide design expertise and engineering support for such cost reduction efforts with a view toward maximal
application of design for manufacturing principles. The Parties acknowledge that they are committed to seeking and achieving cost reductions from the initial unit pricing specified herein and throughout commercial production for the Term of
this Agreement.
 (e) Any rework or replacement activities which are required in connection with field service & customer support
services for the Product will be evaluated by MELA and Askion on a case-by-case basis. Any related charges that are determined to be due to Askion for the rework or replacement field services will be submitted to MELA by Askion in the form of a
quotation which quotation shall be reviewed and approved by MELA before any such rework or replacement activity is performed. 
 (f) Upon
renewal of this Agreement, MELA and Askion may negotiate in good faith a pricing adjustment, provided however no increase in any of the pricing contained herein shall exceed 3% per year. 
 1.8 PAYMENT. (a) Upon shipment of each Matched Pair or Product, Askion shall invoice MELA for such Matched Pair or Product. MELA shall pay such invoices within 30 days of receipt thereof. 

(b) Askion shall invoice MELA for prepaid shipping costs for the Matched Pairs shipped in accordance with MELA’s instructions, and for Product
shipped and delivered by Askion within the European continent, upon the determination by Askion of the actual shipping costs associated therewith. MELA shall pay such invoice within 30 days of its receipt thereof. 

1.9 WARRANTY. 
 (a) Askion warrants that each
Imager, Phantom Fixture and Product will be free from defective workmanship or materials for a period of one year from the date of shipment, and that Askion will remedy such defects through the timely repair or replacement of components deemed to
have been defective. Shipping costs associated with the repair or replacement due to workmanship and materials under the warranty for any Imager, Phantom Fixture or Product will be borne by Askion. 

  
 5 

 (b) Askion further represents that it shall manufacture, integrate, test and provide field
service & customer support, as required hereunder, for each Matched Pair or Product and perform all of its obligations under this Agreement (i) in strict conformity with the Product Specifications, the Testing Procedures, and the
Manufacturing and Testing Services, and in accordance with this Agreement and with all applicable laws, rules and regulations and (ii) in accordance with the current good manufacturing practices (cGMP) applicable to the manufacturing of the
Matched Pairs and Product as defined by Quality System Regulations (QSR) as promulgated under the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq, as amended and in compliance with ISO 13485 required by the Medical
Device Directive (MDD) (93/42/EEC). Askion further warrants and represents that (a) its work hereunder shall be performed in a good and workmanlike manner and that the Matched Pair and Product will be free of any liens and encumbrances,
(b) it has the requisite and necessary experience, all necessary licenses and permits, equipment, facilities and personnel to properly perform the Manufacturing and Testing Services, and (c) it is not a party to any other agreement that
would in any way conflict with, or restrict, its ability to perform the Manufacturing and Testing Services. 
 1.10 FAILURE TO MEET THE
SCHEDULE, PRODUCT SPECIFICATIONS OR TESTING PROCEDURES. MELA shall have the right to reject any Matched Pair or Product that is not in compliance with the Product Specifications and/or Testing Procedures or in conformity with the warranty
obligations of Askion pursuant to Section 1.9 or any other provision of this Agreement. Within thirty (30) days of receiving a nonconforming shipment of a Matched Pair or Product, MELA shall provide Askion with written notice of such
rejection stating the reasons for such rejection. Askion shall as promptly as practicable correct such nonconformity by repairing or remedying the defect or replacing the Matched Pair or Product, in each case at their sole cost and expense including
shipping costs. If Askion is unable to provide corrected deliverables in accordance with the Product Specifications and/or Testing Procedures within 60 days of such written notice, then in addition to any other rights MELA may have hereunder or
under applicable law, at its sole discretion, MELA may (a) extend the correction period, or (b) give written notice of termination of this Agreement (see Article IV). Payment for any Matched Pair or Product shall not constitute acceptance
of any nonconforming or defective Matched Pair or Product. 
 1.11 PRODUCTION TOOLING AND TESTING EQUIPMENT. Upon execution of this Agreement,
Askion shall provide to MELA a list of production tooling and testing equipment, together with the cost thereof, required for the manufacture, integration, and testing of the Matched Pair and Product. Upon written approval of such list by MELA,
MELA, at its option, shall either purchase such production tooling and testing equipment and deliver such equipment to Askion or, instruct Askion to purchase such equipment and upon invoice from Askion, reimburse Askion for its actual and reasonable
out of pocket costs related to the purchase, periodic maintenance, and calibration of such equipment. Should any production tooling or testing equipment require replacement, Askion shall request approval from MELA to replace such production tooling
or testing equipment and, upon written approval from MELA’s Chief Financial Officer, MELA shall be responsible for the cost thereof. MELA shall own and retain title forever to all production tooling and all testing equipment, including, without
limitation, all environmental chambers, purchased or paid for by MELA at any time. 

  
 6 

 1.12 QUALITY ASSURANCE. Askion shall utilize record-keeping, inventory, and other policies and procedures
that allow MELA to comply with U.S. Food and Drug Administration (“FDA”) Quality System Regulations and comparable European standards for the production of medical devices, as well as with CE, ISO 13485, ISO 9001, UL, and similar
standards, as set forth in Appendix IV attached hereto and made a part hereof, which sets forth the agreement between the Parties with respect to their respective responsibilities as to quality assurance obligations and both European Regulatory and
US FDA requirements pertaining to the Imager, the Phantom Fixture and the Product. Askion shall use its best efforts to take all actions necessary to enable MELA to obtain and maintain US FDA and comparable International approvals of the commercial
use of the Product. 
 1.13 PROCEDURES FOR DOCUMENTS. Appendix IV attached hereto and made a part hereof sets out the agreement between the
Parties as to the procedures that shall be utilized for identification of each document created or modified by Askion pursuant to this Agreement in order to ensure that MELA retains final ownership of such documents, while Askion may still integrate
these documents in its own quality control system. At least one version of each such document must have all of its text in the English language. Askion shall keep complete, accurate and authentic accounts, notes, data and records of work performed
under this Agreement, including, without limitation, records pertaining to the methods and facilities used by it for the manufacture, integration, testing, packaging, labeling, warehousing, and shipping, and technical field service &
customer support of the Matched Pair or the Product. 
 1.14 PLANT AND EQUIPMENT. Askion shall conduct all Manufacturing and Testing Services of
the Matched Pair and the Product at its facility located at Gera, Germany, or such other facility as the Parties may agree. Askion shall maintain its facilities, including all equipment or machinery used by Askion in the Manufacturing and Testing
Services, or otherwise required in connection with the services provided under this Agreement, in a state of repair and operating efficiency consistent with the requirements of the Product Specifications. 

ARTICLE II 

REGULATORY RESPONSIBILITY; INTELLECTUAL PROPERTY 
 2.1 REGULATORY APPROVALS. MELA shall undertake and be responsible for the procurement of any and all regulatory approvals and/or registrations and customs approval necessary for sale of the medical
devices incorporating the Product (the “Devices”). MELA shall be responsible for complying with the U.S. Food, Drug and Cosmetic Act and European Medical Device Directive (MDD) (93/42/EEC) and the regulations promulgated there under
for distribution of the Devices in the United States (“FDA Approval”) and European Member States or other countries outside the United States (CE Certification or other national regulations). MELA will maintain a Quality

  
 7 

 
System, certified by a European Notified Body, in accordance with Annex II of the MDD and EN ISO 13485:2003, the European and International standard for medical device quality systems. Appendix
IV attached hereto sets out a description of such policies and procedures. Askion shall cooperate with and use its best efforts to assist MELA in fulfilling the responsibilities set forth in this paragraph. 

2.2 ASKION’S QUALIFICATIONS. Askion shall obtain and maintain in full force and effect during the Term compliance with all EU member states and US
requirements, and other countries to be determined upon the mutual agreement of the Parties, and regulatory authority licenses, permits, registrations, and approvals required in order to manufacture the Matched Pair and the Product pursuant to the
terms hereof. Askion shall be registered with the FDA as a medical device manufacturer as an ISO 13485 certified company and shall notify MELA of any change in that status during the Term of this Agreement. Should Askion lose its status as an
FDA-registered medical device manufacturer or lose its ISO 9001 or ISO 13485 certification, it shall have a period of 90 days to have the certification reinstated and if not reinstated within this cure period, MELA may give written notice of
termination of this Agreement (see Article IV). 
 2.3 INTELLECTUAL PROPERTY: TRADEMARKS AND COPYRIGHTS. MELA shall have the sole right to
prepare, file, prosecute and maintain trademark and copyright applications or registrations or licensing rights thereof with respect to any product (including, without limitation, the Matched Pair and the Product or any product contained therein).
All such applications and registrations shall be at MELA’s expense. MELA shall retain ownership and/or licensing rights of these applications and registrations throughout the Term and in perpetuity. Askion shall from time to time, as MELA may
deem necessary or appropriate, execute and deliver to MELA any and all documents of transfer or assignment relating to the Matched Pair and the Product and cooperate fully in obtaining whatever approval or product protection that MELA may deem
desirable or appropriate. 
 ARTICLE III 
 PRODUCT LIABILITY 
 3.1 NOTICE OF PRODUCT LIABILITY CLAIMS. Each Party shall notify the other
promptly in writing of any product liability claim brought with respect to the Matched Pair or the Product based on alleged defects in the design, manufacture, packaging, or labeling of the Matched Pair or the Product or other adverse claim
regarding the Matched Pair or the Product. Upon receiving such written notice, MELA shall assume and have sole control of the defense of any such claim, including the power to conduct and conclude any and all negotiations, compromises or
settlements. Askion shall promptly comply with all reasonable requests from MELA for information, materials or assistance with respect to the conduct of such defense. 
 3.2 NOTICE OF INVESTIGATION. Askion and MELA shall promptly notify each other in writing of any potential or actual investigation or governmental activity relating to the Matched Pair or the Product.

  
 8 

 3.3 PRODUCT LIABILITY INSURANCE. During the Term Askion shall maintain at its expense in full force and
effect general comprehensive, product liability and business interruption insurance policies, naming MELA as an insured party, with reputable insurers acceptable to MELA at a minimum liability limit of two million U.S. dollars covering the Matched
Pair and the Product. 
 ARTICLE IV 
 TERM AND TERMINATION; FORCE MAJEURE 
 4.1 INITIAL TERM. The initial term of this Agreement shall
commence on the Effective Date and continue for three (3) years from the date thereof (the “Initial Term”). 
 4.2 EXTENSIONS
Following the Initial Term, this Agreement shall renew for successive three year periods (the “Renewal Term”, and together with the Initial Term, the “Term”), unless either Party notifies the other in writing of its intent to
terminate no later than one year prior to the end of the Initial Term or any Renewal Term (see Section 4.5). 
 4.3 TERMINATION BY MELA.
MELA shall have the right to terminate this Agreement (i) pursuant to Sections 1.10 or 2.2 hereof, or (ii) if Askion fails to perform in accordance with this Agreement and fails to cure such default within thirty (30) days of written
notice thereof. In the event of termination pursuant to this Section 4.3, Askion will be required to remove and ship to MELA at Askion’s own expense, all materials, inventory, work in process, finished goods including the Matched Pair or
the Product, tools, fixtures, equipment, drawings and documents previously purchased by MELA being kept under Askion’s control at their or any other facility. 
 4.4 TERMINATION BY ASKION. Askion shall have the right to terminate this Agreement on written notice to MELA only if MELA has failed to make any payments required by this Agreement in the time provided
therefore and following sixty (60) days’ from written notice of such failure from Askion, MELA does not pay all delinquent sums in full; provided, however that this provision shall not apply to any amounts not paid which are disputed in
good faith as being payable hereunder. 
 4.5 TERMINATION BY EITHER PARTY. In addition to their respective rights set forth in Sections 4.3 and
4.4, either Party hereto shall have the right to terminate this Agreement on written notice to the other Party under the following circumstances: 
 (i) by mutual agreement; 
 (ii) in the event that the other Party is declared
insolvent, or bankrupt by a court of competent jurisdiction, or a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other Party, or such other Party shall make or execute an assignment for the benefit of
creditors, or a receiver is appointed by a court of competent jurisdiction over all or a substantial portion of the other Party’s assets and such receivership is not dismissed within 30 days of appointment, or 

  
 9 

 (iii) in the event of the issuance of a final order, decree or other action by any competent
judicial authority or governmental agency (including, without limitation, the FDA) which restrains, enjoins or prohibits the sale or introduction into interstate and/or international commerce of the Matched Pair or Product and such restraint,
injunction or prohibition is not vacated within 30 days thereafter. 
 Under all conditions of termination, both Parties will be bound by all
secrecy and non-disclosure conditions of this Agreement in perpetuity. 
 Under 4.1, 4.2, 4.4 or 4.5 (i), (ii) or (iii) above, at
non-renewal or termination Askion will be responsible to return to MELA all materials, inventory, work in process, finished goods including the Matched Pair or the Product tools, fixtures, equipment, drawings and documents previously purchased by
MELA being kept under Askion’s control at their or any other facility. Shipping of such goods shall be at MELA’s expense. 
 4.6
SURVIVAL. The termination or expiration of this Agreement shall be without prejudice (a) to the rights of any Party to receive upon its request all payments accrued and unpaid, or all documents, data and deliverables not delivered, as of the
date of such expiration or termination; (b) the rights and remedies of either Party with respect to any previous breach or default under any representation, warranty or covenant herein contained; and (c) rights under any other provision of
this Agreement which expressly and necessarily calls for performance after expiration or termination. 
 4.7 FORCE MAJEURE. If the performance
of this Agreement or of any obligation hereunder is prevented, or restricted or interfered with by reason of any event of Force Majeure, the Party so affected, upon prompt notice (stating therein the nature of the suspension of performance and
reasons therefore) to the other Party, shall be excused from performance, but only for the duration of such inability, provided that the Party so affected shall use its best efforts to avoid or remove such causes of nonperformance, and shall
continue performance hereunder with the utmost dispatch whenever such causes are removed. Under no circumstances shall a Force Majeure event relieve either Party of any obligation hereunder for a period of more than ninety (90) days.
“Force Majeure” shall mean acts of God, natural disasters, acts of civil or military authority, government priorities, fire, floods, epidemics, quarantine, energy crises, war or riots. 

ARTICLE V 

INDEMNIFICATION 
 5.1
ASKION’S INDEMNITY. Askion agrees to indemnify, defend and hold harmless MELA, its affiliates, directors, officers, employees, agents and customers, from and against any claims, liabilities, loss or expenses, including reasonable
attorney’s fees, arising out of or in connection with the failure of Askion to perform any of its obligations hereunder or the failure of a Matched Pair or Product delivered hereunder to comply with Askion’s warranties in Section 1.9,
including but not limited to any actual or alleged injury, damage, death or other consequence occurring to any person as a result, directly or indirectly, of such failure, regardless of the form in which such claim is made. 

  
 10 

 5.2 MELA’s INDEMNITY. MELA agrees to indemnify, defend and hold harmless Askion, its affiliates,
directors, officers, employees, agents and customers, from and against any claims, liabilities, loss or expenses, including reasonable attorney’s fees, arising out of or in connection with the marketing, distribution or use of the Matched Pair
or Product or the device into which the Matched Pair or Product is incorporated which is not the result of or related to Askion’s failure to comply with its warranty obligations under Section 1.9 hereof, including but not limited to any
actual or alleged injury, damage, death or other consequence occurring to any person as a result, directly or indirectly, of such failure, regardless of the form in which such claim is made. 
 5.3 PROCEDURES. Each indemnified party agrees to give the indemnifying party prompt written notice of any claims, including any claims asserted or made by any governmental authority, for which the other
might be liable under the foregoing indemnification, together with the opportunity to defend, negotiate and settle such claims. Such notice shall be given to the indemnifying party promptly after receipt of such claim. Failure to provide or promptly
provide such notice shall not release the indemnifying party from any of its obligations hereunder except to the extent that the indemnifying party is materially prejudiced by such failure. Each indemnified party will cooperate fully with the
indemnifying party in defending or otherwise resolving any such action, and each indemnified party in any such action may at its option and expense be represented in such action. No party shall be responsible or bound by any settlement made by any
other party without its prior written consent, provided that such any such party requested to give consent shall not unreasonably withhold its consent to any such settlement. 
 ARTICLE VI 
 TECHNOLOGY OWNERSHIP; CONFIDENTIALITY 

6.1 TECHNOLOGY OWNERSHIP. Unless specifically and expressly granted herein, no licenses or rights under either Party’s intellectual property rights
are implied or granted in this Agreement. Each Party shall retain full ownership of all its intellectual property in existence prior to the date the Parties first entered into an agreement relating to the Matched Pair and Product or developed as a
result of work outside the scope of this Agreement including without limitation that Production Agreement between MELA and Askion, dated as of January 25, 2006 (the “Prior Agreement”). MELA shall have full ownership, with no rights of
ownership vested in Askion, of all inventions and discoveries, including any patent or other intellectual property rights (collectively, the “Inventions”), whether or not patentable, made by Askion or its employees (or any other
third-party) in the course of performing any work under this Agreement, including, but not limited to, the Manufacturing and Testing Services, and the Prior Agreement, whether such Inventions were made by Askion alone or Askion and any other third
party or Askion and MELA jointly. In the event that this Agreement shall be found by a court of competent jurisdiction not to vest full ownership of the Inventions in MELA, Askion hereby irrevocably assigns to MELA the sole and exclusive right,
title and interest in and to all Inventions, including all rights thereunder and relating thereto, in perpetuity and without further consideration. In the event that any such patents are obtained by MELA, Askion shall be automatically licensed to
practice the patented inventions(s) pursuant to 

  
 11 

 
and only within the scope of this Agreement; provided, that nothing in this Agreement shall be construed to grant Askion a license to practice any such patented invention(s) beyond the scope of
this Agreement. MELA, in its sole discretion, shall determine whether or not to obtain patent protection for such inventions or discoveries. Askion agrees, and agrees to cause its employees, to execute all agreements, instruments or filings
determined by MELA to be necessary to document its ownership of any such inventions. The law of inventorship of the United States shall apply to any inventions whether made inside or outside the United States; provided, however, that to the extent
Askion is obligated to pay any fee, tax or other similar charge under German inventorship law as a result of the work performed by Askion or its employees hereunder, MELA shall reimburse Askion for such fees, taxes and charges up to a maximum of
$5,000 without preapproval by MELA. 
 6.2 CONFIDENTIALITY. The Parties shall keep, and shall cause all of their employees, officers and
directors to keep, the existence and terms of this Agreement confidential. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that during the Term and thereafter the receiving Party shall
keep confidential and shall not publish, make use of or otherwise disclose to a third party or use for any purpose other than as provided for in this Agreement any information and materials furnished to it by the other Party pursuant to this
Agreement (collectively, “Confidential Information”), except to the extent that it can be established by the receiving Party by competent proof that such Confidential Information: 

(i) was already known to the receiving Party as shown by its written records, other than under an obligation of confidentiality, at the
time of disclosure by the other Party; 
 (ii) was generally available to the public or otherwise part of the public domain at
the time of its disclosure to the receiving Party; 
 (iii) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; or 
 (iv) was lawfully disclosed to the receiving Party, other than under an obligation of confidentiality, by a third party who had no obligation to the disclosing Party not to disclose such information to
others. 
 Notwithstanding the foregoing, each Party may disclose the other’s Confidential Information and the existence and terms of this
Agreement to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications, prosecuting or defending litigation, complying with applicable governmental regulations (including, without limitation, regulations
promulgated by the U.S. Securities and Exchange Commission) or conducting pre-clinical or clinical trials, provided that if a Party is required by law or regulation to make any such disclosure of the other Party’s Confidential Information it
will give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications, will use its best efforts to secure confidential treatment of such information required
to be disclosed. 

  
 12 

 6.3 SURVIVAL. Sections 6.1 and 6.2 hereof shall survive the termination or expiration of this Agreement.

 ARTICLE VII 
 MISCELLANEOUS 
 7.1 NOTICES. Any notices required or permitted to be given to a Party hereunder
shall be in writing and delivered or sent to such Party at its address given below: 
  

			
	(i) if to Askion:	  	
		
		  	Askion, GmbH.
		  	Gewerbepark Keplerstraße 17-19
		  	D-07549 Gera
		  	Germany
		  	Attn: Lutz Doms
		  	Telephone: + 49 (0) 365 7353 - 401
		  	Facsimile: + 49 (0) 365 7353 - 402
		
	(ii) if to MELA:	  	
		  	MELA Sciences, Inc.
		  	50 South Buckhout Street, Suite 1
		  	Irvington, New York 10533-2204
		  	Attn: Richard I. Steinhart
		  	Telephone: (914) 591-3783, Ext. 736
		  	Facsimile: (914) 591-3701
		
	With a copy to:	  	 Golenbock Eiseman Assor Bell & Peskoe LLP
 437 Madison Avenue
 New York, NY 10022
 Attn: Valerie A. Price, Esq.
 Telephone: (212) 907-7335

Facsimile: (212) 754-0330

 or such other address as such Party may hereafter specify; and shall be deemed given (i) when personally delivered
to such Party; (ii) when transmitted by telecopy and receipt of such transmission is confirmed by telecopy; or (iii) when delivery is confirmed by an established overnight courier service. 

7.2 ATTORNEYS’ FEES. In the event of any litigation, arbitration, judicial reference or other legal proceeding involving the Parties to this
Agreement to enforce any provision of this Agreement, to enforce any remedy available upon default under this Agreement, or seeking a declaration of the rights of either Party under this Agreement, the prevailing Party shall be entitled to recover
from the other such attorneys’ fees and costs as may be 

  
 13 

 
reasonably incurred, including the costs of reasonable investigation, preparation and professional or expert consultation incurred by reason of such litigation, arbitration, judicial reference,
or other legal proceeding. 
 7.3 ASSIGNMENT. Neither Party shall assign or transfer this Agreement or any of its rights or duties hereunder to
a third party without the prior written consent of the other Party hereto; provided, however, that MELA shall be permitted to assign this Agreement to any third party in connection with the sale of its business, whether such sale is consummated as a
sale of all or substantially all of the assets of MELA, a merger, consolidation or similar transaction, the sale of the capital stock of MELA or any other similar transaction. Any purported assignment or transfer in violation of this Section shall
be void ab initio and of no force or effect. 
 7.4 GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws
of the State of New York, without regard to the principles of conflicts of laws of such State. 
 7.5 MEDIATION; SUBMISSION TO JURISDICTION;
VENUE. The Parties agree to attempt to resolve any dispute, claim or controversy arising out of or relating to this Agreement first by mediation, which shall be conducted under the then current mediation procedures of The CPR Institute for Conflict
Prevention & Resolution or any other procedure upon which the parties may agree. The parties further agree that their respective good faith participation in mediation is a condition precedent to pursuing any other available legal or
equitable remedy, including litigation, arbitration or other dispute resolution procedures. 
 Either party may commence the
mediation process by providing to the other party written notice, setting forth the subject of the dispute, claim or controversy and the relief requested. Within ten (10) days after the receipt of the foregoing notice, the other party shall
deliver a written response to the initiating party’s notice. The initial mediation session shall be held within thirty (30) days after the initial notice. The parties agree to share equally the costs and expenses of the mediation (which
shall not include the expenses incurred by each party for its own legal representation in connection with the mediation). 
 The parties further
acknowledge and agree that mediation proceedings are settlement negotiations, and that, to the extent allowed by applicable law, all offers, promises, conduct and statements, whether oral or written, made in the course of the mediation by any of the
parties or their agents shall be confidential and inadmissible in any arbitration or other legal proceeding involving the parties; provided, however, that evidence which is otherwise admissible or discoverable shall not be rendered inadmissible or
non-discoverable as a result of its use in the mediation. 
 Each Party consents to the exclusive jurisdiction and venue of the State of New
York in respect of any mediation, and in the event mediation is not successful, of the federal and state courts located in New York in any action arising out of or relating to this Agreement, waives any objection it might have to jurisdiction or
venue of such forums or that the forum is inconvenient, and agrees not to bring any such action in any other jurisdiction or venue to which either Party might be entitled by domicile or otherwise. 

  
 14 

 Notwithstanding anything to the contrary herein, the Parties agree that the requirements to submit to
mediation herein shall not prohibit any Party from seeking immediate injunctive relief in connection with any dispute, claim or controversy in order to prevent irreparable harm. 
 7.6 ENTIRE AGREEMENT. This Agreement shall constitute the entire agreement between the Parties and shall supersede any other agreements, whether oral or written, expressed or implied, as they pertain to
the subject matter hereof (including, but not limited to, that Production Agreement between the MELA and Askion dated as of January 25, 2006). The whole of this Agreement including all Annexes and Appendices attached hereto are to be taken
together so as to give effect to every part thereof to the maximum extent practicable, with each document helping to interpret the other. 
 7.7
RELATIONSHIP. The relationship created by this Agreement shall be strictly that of independent contractors and shall not constitute a partnership, joint venture or agency. Neither Party is hereby constituted an agent nor legal representative of the
other Party for any purpose whatsoever and is granted no right or authority hereunder to assume or create an obligation, expressed or implied, or to make any representation, warranties or guarantees, except as are expressly granted or made in this
Agreement. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 

7.8 WAIVER. The Parties mutually agree that a waiver by either Party of any right hereunder or the failure to perform or breach of any of the terms of
this Agreement by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party. 
 7.9 SEVERABILITY. The illegality, invalidity or unenforceability of any provision (or any part thereof) of this Agreement shall not affect or limit the legality, validity or enforceability of any other
provision or the other parts of such provision as the case may be, provided the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby. In lieu of any such illegal, invalid or unenforceable
provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties.

 7.10 COUNTERPARTS. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. This Agreement may be executed by facsimile signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 15 

 IN WITNESS WHEREOF, authorized representatives of the Parties have affixed their signatures
as of the date first written above. 
  

					
	MELA Sciences, Inc.	 		 	Askion GmbH
	50 S. Buckhout Street, Suite 1	 		 	Gewerbepark Keplerstrasse
	Irvington, NY 10533 USA	 		 	D-07549
		 		 	Gera, Germany
			
	Signature:	 		 	Signature:
			
	 /s/ Joseph V. Gulfo
	 		 	 /s/ Lutz Doms

	Joseph V. Gulfo	 		 	Lutz Doms
	President/Chief Executive Officer	 		 	Managing Director
			
	On this 11 day of January 2012	 		 	On this 11 day of January 2012SERVICE AGREEMENT, DATED MARCH 21,2012

 Exhibit 10.2 
 SERVICE AGREEMENT 
 BETWEEN 

QUINTILES Commercial Germany GmbH 
 registered address at 
 Schildkrötstrasse 17-19, D-68199 Mannheim, Germany

 hereinafter “QUINTILES” 
 and 
 MELA Sciences Inc. 

registered address at 
 50 South Buckhout St., Irvington, NY 10533, USA 
 hereinafter
“MELA” 

 INDEX: 
  

							
	 1.
	 	SCOPE OF AGREEMENT	  	 	3	  
	 2.
	 	QUINTILES OBLIGATIONS	  	 	3	  
	 3.
	 	MELA OBLIGATIONS	  	 	4	  
	 4.
	 	MUTUAL OBLIGATIONS	  	 	4	  
	 5.
	 	PRICE AND PAYMENT	  	 	5	  
	 6.
	 	LIABILITY AND INDEMNITY	  	 	5	  
	 7.
	 	CONFIDENTIALITY	  	 	6	  
	 8.
	 	DURATION AND TERMINATION	  	 	6	  
	 9.
	 	NON-SOLICITATION	  	 	7	  
	 10.
	 	RETURN OF MATERIALS	  	 	8	  
	 11.
	 	COOPERATION AND GOVERNANCE	  	 	8	  
	 12.
	 	OWNERSHIP AND INVENTIONS	  	 	8	  
	 13.
	 	NOTICES	  	 	9	  
	 14.
	 	ASSIGNMENT AND SUB CONTRACTING	  	 	9	  
	 15.
	 	SURVIVAL	  	 	9	  
	 16.
	 	ENTIRE AGREEMENT	  	 	9	  
	 17.
	 	AMENDMENTS	  	 	9	  
	 18.
	 	JURISDICTION	  	 	10	  

  
 2 / 10

	1.	SCOPE OF AGREEMENT 

  

	1.1.	MELA wishes to appoint QUINTILES and QUINTILES hereby accepts such appointment to perform the Services as described in Schedule I and II in accordance with the terms
and conditions that are agreed hereinafter. 

  

	1.2.	MELA commits to pay to QUINTILES the QUINTILES Service Fees in accordance with the payment schedule and terms of payment as described in Schedule II and to comply with
the MELA obligations as particularly set out in clause 3. of this Agreement. 

  

	2.	QUINTILES OBLIGATIONS 

 It is
agreed that QUINTILES shall: 
  

	2.1.	undertake all reasonable endeavours to deliver the Services as described in detail in Schedule I to this Agreement; 

 

	2.2.	have the Services carried out by qualified pharmaceutical representatives according to §75 AMG (Arzneimittelgesetz – German Medicines Act) – as far as
the detailing of medicines in the sense of §2 Clause 1 and Clause 2 No. 1 AMG are subject of the Services; 

  

	2.3.	ensure that the provided QUINTILES personnel are familiar with the provisions of relevant legislation, codes of practice or guidelines applicable for the project;

  

	2.4.	manage all contractual obligations in respect of the employment of the QUINTILES Personnel including the payment of all salaries, QUINTILES bonuses and benefits;

  

	2.5.	be responsible for the management of the QUINTILES personnel. In conformance with QUINTILES policy, QUINTILES shall provide appropriate employee counseling and
discipline, up to and including termination, to QUINTILES personnel who violate employment rules and who are otherwise underperforming their job responsibilities. QUINTILES will promptly follow-up on any reports made by MELA of a QUINTILES personnel
non-compliance or underperformance and will apply such counseling or discipline as may be warranted in QUINTILES’s sole judgment 

  

	2.6.	ensure that the QUINTILES personnel will comply with all processes and procedures put in place by MELA, the marketing authorisation holder of the Product, for the
reporting of adverse events and for responding to scientific questions raised by physicians; 

  

	2.7.	inform MELA about the status of the Services performed on a regular basis throughout the entire duration of the project. 

  
 3 / 10

	3.	MELA OBLIGATIONS 

 Throughout the
duration of this Agreement MELA hereby agrees that MELA shall: 
  

	3.1.	pay the QUINTILES Service Fees in full and in accordance with the payment terms as set out in Schedule II to this Agreement; 

 

	3.2.	provide QUINTILES with an adequate level of training and knowledge that is necessary to carry out its duties and to provide the Services; specifically MELA shall be
responsible for the training of the QUINTILES personnel on disease areas and product knowledge; 

  

	3.3.	be responsible for putting in place the processes and procedures necessary to ensure that adverse events are reported as required to MELA and to the relevant
Authorities in accordance with the regulations by law (AMG – German Medicines Act / MPG – German Medical Devices Act) and that a scientific service is available to respond to scientific questions raised by physicians;

  

	3.4.	provide QUINTILES with marketing support and marketing materials to be used for the detailing of the products, with product samples (if applicable) and with ongoing
sales data; 

  

	3.5.	ensure that all provided marketing material is in accordance with applicable legal requirements and that the over-all Promotional Program shall not require or encourage
any one or more of the QUINTILES personnel to offer, pay, solicit or receive any remuneration from or to physicians to induce referrals or purchase of the MELA Product. 

 

	3.6.	ensure that all requisite licenses, approvals, permissions and consents necessary for the legitimate promotion, marketing, sales and distribution of the Product are in
place throughout the duration of this Agreement; 

  

	3.7.	have the right to instruct and access the QUINTILES personnel for all medical and scientific information on the product and product related matters;

  

	3.8.	ensure that MELA’s relevant personnel are fully briefed as to the role of QUINTILES in order to enable smooth communication in the course of the project.

  

	3.9.	to inform the QUINTILES Project Manager at least three months prior to the agreed project end with a binding confirmation in writing, if MELA intends to take over
QUINTILES employees at the end of the project term. 

  

	4.	MUTUAL OBLIGATIONS 

 QUINTILES and
MELA hereby agree: 
  

	4.1.	that the QUINTILES Project Manager shall be informed immediately if MELA should not be satisfied with the delivery of the Services or find deficiencies; QUINTILES shall
immediately implement suitable measures to resolve the problems; 

  
 4 / 10

	4.2.	to decide upon an extension of the project the latest three months prior to the agreed project end as set out in Schedule I; 

 

	4.3.	to inform the respective other party immediately if any Product Risks or Adverse Events become known to either party; 

 

	4.4.	that each party will appoint a responsible Project Manager who shall be the primary point of contact during the term of this agreement (see Schedule I)

  

	4.5.	to carry out the Services in compliance with all relevant laws, rules and regulations applicable under the jurisdiction of Germany in which the Services are performed
and to ensure that all personnel involved in the Services are familiar with and comply with the provisions of any such laws, rules and regulations. 

  

	5.	PRICE AND PAYMENT  

The prices, payment schedule, pass through costs and terms of payment for the Services are specified in Schedule II and are important
parts of this agreement. 
  

	6.	LIABILITY AND INDEMNITY 

  

	6.1.	If not ruled differently in clause 6.2 QUINTILES will have unlimited liability for damages according to the relevant legal regulations of the German law.

  

	6.2.	QUINTILES shall not be liable for the slight negligence of minor obligations resulting from this Agreement. Neither QUINTILES, nor any of QUINTILES’ directors,
officers, employees, subcontractors or agents shall have any liability of any type (including, but not limited to, contract, negligence, and tort liability), for any loss of profits, opportunity or goodwill, or any type of indirect or consequential
damage or loss in connection with or arising out of this Agreement, or the Services performed by QUINTILES hereunder. In addition, in no event shall the collective, aggregate liability (including, but not limited to, contract, negligence and tort
liability) of QUINTILES under this Agreement exceed the amount of Service Fees actually payable to QUINTILES. Nothing herein is intended to exclude or limit any liability for willful misconduct or any liability for death or personal injury
caused by negligence. 

  

	6.3.	MELA shall hold harmless and protect QUINTILES against all damage claims and connected costs raised by third parties in the frame of the Services if they are raised in
connection with the products of MELA or the materials provided by MELA. This does not hold if the damage with the third party was caused intentionally or grossly negligent by QUINTILES. Over and above this, MELA is obliged to make adequate
provisions to prevent and limit damages. 

  
 5 / 10

	7.	CONFIDENTIALITY 

  

	7.1.	QUINTILES and MELA each undertake not to disclose or permit to be disclosed to any third party, or otherwise make use of or permit to be made use of, any confidential
information which comes into its possession under this Agreement. 

  

	7.2.	QUINTILES and MELA shall undertake to ensure that all information disclosed under this Agreement remains confidential to those personnel who require that information in
order to carry out their obligations under this Agreement. QUINTILES shall ensure that all QUINTILES employees are made aware of the requirements of this Agreement. 

 

	7.3.	The obligations of the parties in Clauses 7.1 and 7.2 shall not extend to any confidential information which: 

	 	•	 	 is or becomes generally available to the public otherwise than by reason of a breach by the recipient of the clauses above; or

  

	 	•	 	 is known to the recipient party and is at its free disposal prior to its receipt from the other; or 

 

	 	•	 	 is subsequently disclosed to the recipient party by a third party who is not under the obligation of confidence; or 

 

	 	•	 	 QUINTILES or MELA may be required to disclose under any statutory, regulatory or similar legislative requirements subject to the imposition of the
obligations of secrecy wherever possible in that relationship; or 

  

	 	•	 	 is disclosed by QUINTILES to a third party to such extent only as is necessary for the purposes of this Agreement and subject to QUINTILES using all
reasonable endeavours to ensure that the person in question keeps the same confidential and does not use the same except for the purposes for which the disclosure is made. 

 

	7.4.	The obligations of QUINTILES and MELA under this Clause 7 shall survive the termination for whatever reason of this Agreement for five years. 

 

	8.	DURATION AND TERMINATION 

  

	8.1.	This Agreement commences on the date of signature hereof and shall continue for the period specified in Schedule I, subject to early termination on notice in accordance
with clause 8.2., 8.3., 8.4. or a mutual agreement on the extension of the project according to 4.2. 

  

	8.2.	Either party shall have the right to terminate this Agreement if the other party commits any material breach of this Agreement, and, in the case of a breach capable of
remedy, fails to remedy the same within thirty (30) days after receipt of a written notice giving particulars of the breach and confirming the intention to terminate if not remedied. 

 

	8.3.	 If either party shall become bankrupt or insolvent or if all or a substantial part of its business or assets shall be placed in the hands of a
Receiver, Administrator, 

  
 6 / 10

	 	
Administrative Receiver, Liquidator, Trustee in Bankruptcy or similar officer or an insolvency practitioner, whether by its voluntary act or otherwise then this Agreement and the rights granted
herein shall immediately be subject to termination at the option of the other party. 

  

	8.4.	 QUINTILES and MELA agree that MELA shall have the right of an early termination at will the earliest after 12 month project duration with a notice
period of 3 months to the new effective termination date (e.g. giving notice on the 31st Dec. to terminate on the 31st March). In such a case MELA has to pay the full Quintiles Service Fees (Daily Rates) for all provided staff until the actual end of the project (the new effective termination date). If Quintiles
is able to deploy members of the provided staff to a new QUINTILES Project prior to the new effective termination date, the obligation of MELA to pay the Daily Rates for such an individual will terminate at the date of their effective assignment to
the new project. 

  

	8.5.	Any termination of this Agreement shall not affect the accrued rights of either QUINTILES or MELA arising under or out of this Agreement and all provisions which
expressly or by implication survive this Agreement; they shall remain in full force and effect. 

  

	9.	NON-SOLICITATION 

  

	9.1.	MELA hereby undertakes to QUINTILES that at no time during the Project Term MELA and/or any of its Affiliates shall: 

 

	 	(a)	make any offer of employment or enter into any discussions or negotiations with a view to making any offer of employment to any person employed by QUINTILES in
providing all or any part of the Services hereunder (“Relevant Employee”); or 

  

	 	(b)	solicit or attempt to solicit services from any Relevant Employee on their own account or entice or attempt to entice any Relevant Employee away from QUINTILES; or

  

	 	(c)	have business dealings with or attempt to have business dealings with any Relevant Employee (other than pursuant to this agreement). 

 

	9.2.	In the event that any Relevant Employee providing any of the Services referred to herein should accept employment with MELA, or any of its Affiliates, during the term
of their respective Assignments and/or during the Project Term (including any extensions thereof), or start to provide services to MELA, or any of its Affiliates, the same as or similar to the Services either as an individual or through a third
party during the term of their respective Assignments under this Agreement (including any extensions thereof), QUINTILES will charge and MELA will pay a Take-on Fee of 25% of the annual contracted basic salary or fee offered to such Relevant
Employee upon commencement of their employment at MELA or any of its Affiliates. 

  
 7 / 10

	9.3.	For the avoidance of doubt no Take-on Fee shall be payable by MELA upon the date of expiry of the agreed Project Term (as referred to in Schedule I) or, if
extended, upon the date of expiry of any such extension to the Project Term. 

  

	10.	RETURN OF MATERIALS 

QUINTILES shall within 30 days of termination of this Agreement at the request of MELA destroy or return at the expense of MELA all
materials belonging to MELA other than those which QUINTILES has an obligation to archive. Nothing in this Agreement shall be construed to transfer from MELA to QINTILES any FDA or regulatory record-keeping requirements. 

 

	11.	COOPERATION AND GOVERNANCE 

  

	11.1.	All data and information in the possession of MELA or under his control necessary for QUINTILES to conduct the Services will be forwarded by MELA to QUINTILES.
QUINTILES shall not be liable to MELA nor be deemed to have breached this Agreement for errors, delays or other consequences arising from MELA’s failure to timely provide documents, materials or information. The cooperation between MELA and
QUINTILES has to enable QUINTILES at all times to fulfil its contractual obligations in time and in full. If MELA, for reasons other than a breach by QUINTILES, delays an agreed starting date for the Services or suspends performance of the Services,
QUINTILES reserves the right to maintain to claim its fees. 

  

	11.2.	For the ongoing governance of the project QUINTILES and MELA agree to establish a Joint Steering Committee that should hold regular local meetings (e.g. every 3-4
months in Mannheim) to discuss and decide on all relevant business topics for the MELA sales activities in Germany. The Joint Steering Committee shall be formed by the MELA Project Leader, the QUINTILES Project Manager, the responsible QUINTILES
Business Unit Director and the National Business Manager. Other relevant members of the MELA and Quintiles Management Staff could join the meetings as needed. 

 

	12.	OWNERSHIP AND INVENTIONS 

  

	12.1.	All MELA patents, trade secrets, copyrights, trade names, trademarks, service marks, proprietary data and materials or intellectual property and all improvements to any
of the foregoing used in connection with the Services provided pursuant to this Agreement shall remain the sole and exclusive property of MELA and QUINTILES rights to use such MELA Property shall be limited to those permitted by this Agreement.

  

	12.2.	Notwithstanding the foregoing, MELA and QUINTILES agree that all QUINTILES property (including but not limited to certain analytical methods, procedures and techniques,
manuals, financial information, technical expertise and software) or improvements thereto which are used, improved, modified or developed by QUINTILES under or during the term of this Agreement are the sole and exclusive property of QUINTILES.

  
 8 / 10

	13.	NOTICES 

 Any
notice or other communication to be given under this Agreement shall be in writing and delivered personally or sent by facsimile transmission or first-class registered mail. 

 

	14.	ASSIGNMENT AND SUB CONTRACTING 

  

	14.1.	This Agreement may not be assigned by QUINTILES or MELA to any third party without prior written consent of the other party, which will not be unreasonably withheld.

  

	14.2.	With prior written consent from MELA, which will not be unreasonably withheld, QUINTILES shall be entitled to use agents and sub-contractors to carry out the Services
provided that QUINTILES will be responsible for the acts and omissions of such agents and sub-contractors as if the Services were performed by QUINTILES. 

  

	15.	SURVIVAL  

 The
rights and obligations of MELA and QUINTILES, which by intent or meaning have validity beyond termination or completion of this Agreement (including, but not limited to, rights with respect to confidentiality, liability and indemnity, ownership and
inventions) shall survive the termination or completion of this Agreement. 
  

	16.	ENTIRE AGREEMENT  

This Agreement including all Schedules contains the entire understanding of the parties with respect to the subject matter herein, and
supersedes all previous agreements (oral and written), negotiations and discussions. 
  

	17.	AMENDMENTS  

  

	17.1	Any material amendment or change of the details of this Agreement (including, but not limited to, changes in an agreed starting date for the Services, the nature of the
Services or the number of team members) must be in writing and executed by duly authorised representatives of MELA and QUINTILES. Both parties agree to act in good faith and promptly when considering a written amendment or change requested by the
other party. The amendment shall not affect the accrued rights of either QUINTILES or MELA arising under or out of this Agreement and all provisions which explicitly or by implication survive this Agreement shall remain in full force and effect.

  
 9 / 10

	17.2	Where any provisions of this Agreement shall be invalid or impracticable, such invalidity or impracticability shall not affect any other provision hereof. In such case,
QUINTILES and MELA agree to replace any invalid or impracticable provision by a valid and practicable provision that captures the meaning and purpose of the invalid or impracticable provision. The same goes for omissions in the agreement.

  

	18.	JURISDICTION 

  

	18.1.	This Agreement shall be governed by the laws of Germany and is subject to the jurisdiction of the German Courts. 

 

	18.2.	If both parties are going to settle any disputes by an arbitration process, this arbitration process shall be ruled according to the guidance of the American Chamber of
Commerce in Germany (AmCham Germany) in Frankfurt. 

  

	18.3.	No failure or delay on the part of QUINTILES or MELA to exercise or enforce any rights granted under this Agreement shall be interpreted or operate as a waiver thereof.

 For and on behalf of QUINTILES Commercial Germany GmbH 

 

									
	Date:	 	 21 March 2012
	 		 		 	
					
	Signature:	 	 /s/ Monika Beintner
	 		 	Signature:	 	 /s/ Peter Kurtz

					
	Name:	 	 Monika Beintner
	 		 	Name:	 	 Peter Kurtz

					
	Function:	 	 Managing Director
	 		 	Function:	 	 Key Account Director

 For and on behalf of MELA Sciences Inc. 

 

									
	Date:	 	 March 19, 2012
	 		 		 	
					
	Signature:	 	 /s/ Joseph V. Gulfo
	 		 	Signature:	 	  

					
	Name:	 	 Joseph Gulfo
	 		 	Name:	 	  

					
	Function:	 	 President & CEO
	 		 	Function:	 	  

  
 10 / 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]